Table 4. Hazard ratio for risk of flare: Unadjusted Cox regressions.
| Variable | Hazard ratio | 95% CI | P-value |
|---|---|---|---|
| Demographics | |||
| Male, gender | 1.49 | 0.33, 6.76 | 0.605 |
| Age at RTX, continuous | 0.97 | 0.92, 1.02 | 0.234 |
| Clinical-radiological variables | |||
| Number of involved organs (≥3 organs) | 2.23 | 0.61, 8.14 | 0.225 |
| Kidney involvement | 0.64 | 0.20, 2.03 | 0.450 |
| Pancreas involvement | 1.08 | 0.36, 3.29 | 0.887 |
| Bile ducts involvement | 0.72 | 0.23, 2.27 | 0.577 |
| Retroperitoneum involvement | 1.31 | 0.28, 6.20 | 0.733 |
| IgG4-RD RI (>9) | 3.68 | 1.07, 12.62 | 0.038 |
| Biological variables before RTX | |||
| Serum IgG4 (≥135 mg/dl) | 1.38 | 0.30, 6.40 | 0.685 |
| Hypergammaglobulinemia (>15 g/l) | 1.10 | 0.37, 3.29 | 0.864 |
| Eosinophilia (>0.5 G/l) | 0.60 | 0.16, 2.24 | 0.450 |
| Hypocomplementemia | 1.31 | 0.32, 5.29 | 0.705 |
| CRP (>10 mg/l) | 1.03 | 0.31, 3.50 | 0.957 |
| Treatment variables | |||
| Therapeutic lines before RTX (≥2) | 1.4 | 0.45, 4.48 | 0.559 |
| RTX regimen (1 g x2 vs 375 mg/m2 x4) | 2.39 | 0.50, 11.37 | 0.273 |
| GC maintenance therapy | 0.94 | 0.31, 2.83 | 0.911 |
| RTX prophylactic maintenance therapy | 0.18 | 0.04, 0.84 | 0.029 |
Values in bold show statistical significance. CI, confidence interval; CRP, C-reactive protein; GC, glucocorticoid; RI, Responder Index; RTX, rituximab.